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ABSTRACT
Fetal survival and development is supported by the maternal immune system. Questions regarding those mechanisms have 
risen from development of transplantation medicine and observation of graft rejection. Initial theories of anatomic division, 
fetal immune immaturity and maternal immune system inertia were found incorrect. Rejection of fetal “semi-allograft” by 
maternal immune system could result in pregnancy loss. Two pregnancy losses of any etiology are considered recurrent 
and effort should be made to name the probable cause. Immune causes of pregnancy loss are probably multifactorial, 
thus difficult to research and implement findings in clinical practice. Although a full understating of pregnancy loss is not 
established, new therapies are being developed. This review summarizes the role of lymphocytes in pregnancy develop-
ment, presents data from studies on recurrent pregnancy loss patients, evidence of new therapies and ESHRE guidelines 
regarding immunologic investigations.
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INTRODUCTION
From an immunological perspective pregnancy is an in-
teresting phenomenon. On one hand the fetus requires 
maternal protection from pathogens, on the other develops 
tolerance for paternal antigens. Interest in immunology of 
pregnancy started in the beginning of the transplantation 
era with the observation of transplant rejection mechanisms 
and natural fetal protection against such rejection. 
First, classic theory was presented in 1953 by Peter 
Medawar, who is considered the founder of reproductive 
immunology. He described three mechanisms — anatomic 
division between mother and fetus by placental barrier, 
antigenic fetal immaturity, and inertia of the maternal im-
mune system [1]. In the following years all three of these 
mechanisms where questioned and found incorrect [2]. 
Human placenta stays in contact with maternal blood. 
Trophoblast cells invade uterine spiral which is a crucial part 
of placental development. Pathological placentation plays 
a major role in development of such pregnancy disorders 
as placenta precerta, acareta, incerta or preeclampsia [3]. 
Full contact of maternal and fetal cells, especially ex-
travillous trophoblast (EVT) cells, enforce development of 
an active tolerance to paternal antigens. Fetal antigens are 
recognized by maternal innate and adaptive immune sys-
tems. Both these elements play role in correct development 
of materno-fetal interface. 
KEY LYMPHOCYTES POPULATIONS  
IN PREGNANCY AND RECURRENT 
PREGNANCY LOSS
NK cells are, separate from T and B lymphocytes, lympho-
cytes with cytotoxic and cytokine producing abilities. Dis-
tinct subpopulation of NK called uterine NK (uNK) are pre-
sent in large numbers in endometrium and decidua  [4]. 
Another lymphocyte populations playing important roles in 
pregnancy are Treg and Th17 cells.  These are two distinct lym-
phocyte subpopulations of with contradictory roles in the hu-
man body. Recent development of reproductive immunology 
shows that correct balance of these cells may be important in 
maintaining healthy pregnancy development [5].
Recurrent pregnancy loss (RPL) is defined as loss of 
two or more pregnancies before reaching viability. Prob-
ably 1–2% of couples suffer from RPL [6]. Most common-
ly described causes are anatomic defects of the uterus 
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(e.g. adhesions, myomas, endometrial polyps and congenital 
anomalies), chronic endometritis, antiphospholipid syn-
drome, inherited thrombophilia, endocrine pathologies, 
fetal and parental genetic factors, and immunological imbal-
ance [6, 7]. RPL is not only a medical problem of decreased 
fertility in couples, but also a large psychological burden [8].
At current we can explain only about 50% of RPL. Prob-
ably large proportion of unexplained RPL is caused by im-
mune factors [9]. Research could lead to development of 
new promising therapies and increase chances for successful 
pregnancy in couples suffering from RPL. 
This paper aims to present a literature review of the role 
of key lymphocyte populations in RPL, promising therapies 
of this clinical problem, and available guidelines regarding 
immunological investigation. 
TH17
Th17 cells are adaptive immunity cells characterized by 
interleukin-17 (IL-17) production. Other important cytokines 
produced by Th17 are interleukin-22 (IL-22) and granulo-
cyte-macrophage colony stimulating factor (GM-CSF). Physi-
ologically Th17 cells promote inflammation, especially dur-
ing bacterial and fungal infection [10].
Th17 cells are formed from naïve CD4+ T cells through 
IL-6 and TGF-β stimulation [11]. These cells possess a cer-
tain amount of plasticity that can change cytokine profile 
to Th1 or Treg. This plasticity is present in vivo during the 
course of inflammation [12]. 
TREG
Treg cells are CD4+ lymphocytes characterized by ex-
pression of forkhead-box P3 (FoxP3) transcription factor. 
Foxp3 plays a role in immunoregulation. Its deficiency ame-
liorates the natural history of severe autoimmune disease 
such as immune dysregulation, polyendocrinopathy, enter-
opathy, X-linked (IPEX) syndrome [13].
Treg cells regulate immune response by direct interac-
tion with antigen presenting cells, mainly by cytotoxic T-lym-
phocyte antigen 4 (CTLA-4), secretion of TGF-β, IL-35 and 
IL-10 which are anti-inflammatory cytokines, inducing B cell 
apoptosis through granzymes and high expression of CD25, 
IL-2 receptor, which depletes IL-2 from the environment [13]. 
UTERINE NK
Uterine NK subset is distinct from peripheral NK 
cells. They have lower cytotoxic and higher immunosup-
pressive potential. UNK cells are the most abundant lym-
phocyte subset in human decidua. 60–70% of all uterine 
lymphocytes are uNK [14]. Numbers of uNK cells differs 
during menstrual cycle and pregnancy. In the prolifera-
tory phase uNK compose 10% of all endometrial stromal 
cells, 20% in late secretory phase and even 30% of stromal 
cells in the first trimester. Mature forms of human chorionic 
gonadotropin (hCG) with N-linked carbohydrate side chains 
act through CD206 (mannose receptor) and enhance uNK 
proliferation [15]. 
As other NK cells, uNK are CD56+ and CD3- but lack ex-
pression of CD16 which is responsible for antibody depend-
ent cellular cytotoxicity (ADCC). Moreover uNK cells have 
potential to produce large amounts of cytokines needed 
in proper development of early pregnancy [15]. 
Killer immunoglobin-like receptors (KIR) are receptors 
expressed mainly on NK cells and, depending on type of 
receptor. KIR binds to trophoblast expressed HLA class C 
molecules. Certain combinations of KIR and HLA-C hap-
lotypes result in poor uNK activation and increases risk of 
pregnancy loss. At the same time HLA-G and HLA-E binds 
to another highly expressed receptor NKG-2A, which result 
in inhibition of uNK cytotoxicity [15].
IMMUNE SYSTEM INVOLVEMENT IN RPL
Immunological response to pregnancy probably begins 
even before pregnancy itself occurs. Murine models show 
that paternal antigens derived during coitus are detected 
in female lymph nodes. Two days after coitus, Treg lympho-
cytes reactive to paternal antigens are present in large num-
bers in lymph nodes draining the uterus, peripheral lymph 
nodes and spleen [16]. Interestingly, concentration of TGFβ, 
cytokine needed in Treg differentiation, in seminal plasma is 
one of the highest detected in biological fluids [17].
Implantation of conceptus requires a delicate game of 
pro- and anti-inflammatory factors. IL-6 which is a potent 
proinflammatory cytokine and blocker of Treg differentia-
tion [11], also increases trophoblast invasion [3]. Moreover 
IL-6 and IL-1β expression is decreased in endometrium of 
women suffering from pregnancy loss [18] while IL-6 levels 
in peripheral blood increases [19, 20]. IL-6 and IL-1β  are 
pro inflammatory cytokines. Anti-inflammatory cytokine 
IL-10, which is produced by Treg cells inhibits trophoblast 
invasion [3]. 
Further development of fetus is also upkeeped and 
regulated by the maternal immune system. Decidualiza-
tion is a process of endometrium remodeling in response 
to embryo implantation. This results in proper environment 
for the developing fetus, which needs nourishment from 
the maternal vascular system. To provide proper blood flow 
trophoblast cells invade zona intima of maternal spiral arter-
ies and change their morphology allowing increased blood 
flow. Surprisingly extra villous trophoblast cells form plugs 
within maternal spiral arteries, until the end of the first tri-
mester. This causes decrease blood flow and enables proper 
development of the villous trophoblast and arterial remod-
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eling [21]. Process of arterial remodeling is regulated mainly 
by uNK cells. Immune imbalance is one of the probable etio-
logical factors for idiopathic recurrent pregnancy loss. Such 
imbalance was detected in several studies. Liu et al. com-
pared lymphocyte numbers from peripheral blood of three 
groups of patients — unexplained spontaneous recurrent 
pregnancy loss (URPL), fertile nonpregnant, and pregnant 
women in confirmed viable pregnancy. Additionally, 6 de-
cidual samples form URPL patients were immunoassayed 
and compared with samples from elective termination preg-
nancies. Nonpregnant women and normal early pregnancies 
had similar number of peripheral Th17 cells. URPL women 
had significantly higher number of Th17 cells. Number of 
peripheral Treg cells where similar in nonpregnant and URPL 
women, while normal early pregnancies had higher num-
ber of peripheral Treg cells. Th17/Treg ratio was higher in 
URPL women than in both other groups. Immunostaining 
of decidual samples showed higher prevalence of Th17 in 
decidua of URPL patients than in elective pregnancy termi-
nation cases [22].
Lee et al. conducted a study comparing peripheral blood 
Th17 and Treg ratios in nonpregnant females with URPL and 
normal fertile women. Study showed statistically higher 
numbers of Th17 and increased Th17/Treg ratio in URPL 
women [23].
Study Saifi et al. compared percentage and cytokine 
profiles of Th17 and Treg lymphocytes in peripheral blood 
of nonpregnant URPL suffering and fertile women. Fertile 
women had significantly higher (9.5% ± 0.52) percentage of 
Treg cells than URPL group (5.66% ± 0.21). Th17 lymphocytes 
percentage was lower in fertile women (1.82% ± 0.11) than in 
URPL group (2.8% ± 0.18). Also higher expression of IL-6, 
IL-17 and IL-23 was found in URPL women [20].
Recent study by Qian et al. compared pregnant and 
non-pregnant URPL women with pregnant and non-preg-
nant controls. All groups had similar numbers of periph-
eral blood mononuclear cells but differ in Treg percent-
age. Pregnant control group had higher proportion of Treg 
lymphocytes than nonpregnant control, while there was 
no significant change between pregnant and nonpreg-
nant URPL patients. Moreover, pregnant URPL patients had 
lower Treg percentage in peripheral blood than pregnant 
controls. There was no difference in IL-10 and CTLA-4 ex-
pression in peripheral blood between groups. They both 
take action in Treg activation. No difference in Th17/Treg 
ratio in peripheral blood was found in this study. Investiga-
tors collected also decidual samples from URPL patients 
and women undergoing elective termination of pregnancy. 
Decreased proportion of Tregs and increased proportion of 
Th17 was found in URPL patients. Il-10 expression in Treg did 
not differ between groups, but expression of CTLA-4 was 
lower in URPL women [5].
POTENTIAL THERAPIES
With our current knowledge of causes of immune re-
lated recurrent miscarriage, arise questions of possible 
therapies. In fact, there where trials conducted, some with 
promising results.
Intravenous immunoglobulin (IVIG) administration is 
proposed to immunomodulate maternal response therefore 
improving pregnancy outcome. Study of IVIG treatment and 
NK cell function and levels was conducted by Ahmadi et al. 
Investigators recruited 78 women with recurrent pregnancy 
loss, 38 in intervention arm and 40 as a control group. Af-
ter confirmation of pregnancy, treatment group received 
400 mg/kg IVIG iv. each 4 weeks until 32 weeks of pregnancy. 
Both groups received standard high-risk pregnancy care. 
Live birth rate was 86.8% in treatment group and 45% in 
control group (p = 0.0006). IVIG treatment also significantly 
lowered risk of preeclampsia, gestational diabetes and pre-
term birth. IVIG treatment significantly lowered peripheral 
NK cell cytotoxicity and frequency. Investigators did not 
asses uterine NK population [24].
Randomized controlled trials of IVIG treatment yield 
conflicting results. Most recent metanalysis was performed 
by Egerup  et al. It was conducted according to The Cochrane 
Handbook for Systematic Reviews of Interventions meth-
odology and strict study protocol. It analyzed outcome 
of IVIG treatment and scope for calculation of sample size 
enough to draw definite conclusions. Authors conclude that 
probably there is a different effect of treatment in primary 
and secondary recurrent miscarriage patients. Potential 
beneficial effect of IVIG could be achieved in secondary 
miscarriage patients, but sample size in both subgroups of 
metanalysis where too small to establish definite conclu-
sions. Moreover, the treatment group had more maternal 
adverse effects than placebo group, with no difference in 
neonatal adverse effects. Authors conclude that there was 
not enough evidence to give clear clinical recommenda-
tions, and IVIG treatment should not be used out of a clinical 
trial setting. Different conclusions could be made when new 
evidence will be published [25].
Another widely discussed intervention is paternal or un-
related donor lymphocyte therapy. Most recent metanalysis 
of this approach was published by Cavalcante et al. It  sums 
up evidence coming from 6 other metanalysis. Four of them 
found significant improvement in live birth rate, with OR 
1.16 (95% CI 1.04–1.34), 1.21 (95& CI 1.04–1.37), 4.02 (95% 
CI 3.23–5.00), 3.13 (2.56–3.82). One of the metanalyses 
which shows no improvement with lymphocytes therapy 
is Cochrane Review published in 2014 [26]. This metanalyses 
is widely criticized for including one very poor-quality trial 
showing no effect of lymphocyte therapy. Removal of that 
study from the Cochrane Review resulted in OR 1.63 (95% CI 
1.13–2.35) for live birth. In conclusion the authors remarked 
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that with improvement of diagnostic and treatment proto-
cols lymphocyte immunotherapy should have its place in 
RPL treatment [27].
A recently published non-randomized trial by Liu et 
al. describes successful treatment of 65 patients with low 
dose (1x107) lymphocytes. Investigators showed that this 
kind of therapy alters unfavorable Th1/Th2/Treg ratio and 
significantly decreases miscarriage rate from 34.78% in the 
control group to 11.68% in the treatment group. There was 
no serious adverse events in treatment group, but some 
patients had reactions in place of administration [28].
Retrospective analysis of 241 patients treated by pa-
ternal lymphocyte immunization published by Motak-
Pochrzęst and Malinowski showed promising results. Of 
241 patients 206 received 2–6 paternal lymphocytes im-
munization to induce blocking activity measured by mixed 
lymphocytes reaction test. The control group were 36 pa-
tients with high-risk pregnancy care. Investigators showed 
increased rate of successful pregnancies in treatment group 
(83.7% vs. 36.1%, p < 0.05) [29].
Retrospective study of Cetin et al. analyzing the use of 
low molecular weight heparin (LMWH) in selected popula-
tion of patients with methylene tetrahydrofolate reduc-
tase (MTHFR) mutation could be of benefit. 121 women 
with hetero- and homozygotic MTHFR mutations, 53 in 
the intervention arm with prophylactic dose of LMWH and 
68 in control arm, was included in the study. Both groups 
received folic acid (5 mg/day) and iron (80 mg/day) supple-
mentation. LMWH group had higher live birth rate (69.8% 
vs. 48.5%, p = 0.015) and lower congenital anomalies rate 
(3.3% vs. 17.6%, p = 0.022). Treatment group delivered two 
weeks later (34.88 vs. 32.75) comparing with supplemen-
tation only group but this result did not reach statistical 
significance (p = 0.060) [30].
Recent Bayesian network metanalysis by Lv et al. 
summed evidence on use of 14 different RPL treatments and 
placebo. 49 randomized controlled trials and 8469 patients 
were included. Three different endpoints — miscarriage, live 
birth and successful pregnancy defined as birth of a viable 
fetus, were taken into account. Enough data was available 
to conclude that treatment with corticosteroids + low dose 
aspirin + unfractioned heparin, low dose aspirin +, and 
Granulocyte colony stimulating factor (G-CSF) are effec-
tive in decreasing RPL rates and increasing live births in 
both unexplained RPL and RPL with identified cause. There 
were no statistically significant differences between each 
of the mentioned above treatments.  Additionally authors 
made analysis for antiphospholipid syndrome patients and 
concluded that none of the analyzed treatments performed 
better than placebo [31]. 
IMMUNOLOGICAL INVESTIGATIONS 
GUIDELINES
The most up to date available guideline is that pub-
lished by the European Society of Human Reproduction and 
Embryology. It is a guideline solely dedicated to recurrent 
pregnancy loss. The guideline was developed based on 
evidence published until 31 march 2017. In light of current 
evidence the authors recommend only antiphospholipid 
syndrome screening, and HLA class II determination in se-
lected population. No other immunological diagnostic tests 
should be performed, as it won’t lead to better treatment or 
prognosis. Women who fulfil laboratory criteria of phospho-
lipid syndrome and had 3 or more pregnancy losses should 
be offered low dose aspirin (75–100 mg) before conception 
and prophylactic dose heparin at time of positive pregnancy 
test. IVIG ant lymphocyte therapy are not recommended in 
light of current evidence and should be used only in clinical 
trial setting. As a result of lack of randomized controlled 
trials, recommendations are made based on moderate and 
low quality evidence [6].
SUMMARY
Reproductive immunology has come a long way since 
Peter Madawar’s first ideas. Yet we are still far from fully un-
derstanding exact mechanisms of immunology of embryo 
development and finding evidence-based treatment for 
RPL. On the other hand, many trials have brought interest-
ing possibilities and give hope for patients suffering from 
recurrent pregnancy loss. 
Christiansen et al.  postulated that because of the 
evolutionary need for reproductive success most of mis-
carriages including those of immunological background 
are multifactorial. A single cause with strong association 
with recurrent pregnancy loss would be eradicated from 
gene pool. As a result research and treatment of recurrent 
pregnancy loss is extremely difficult [9]. Probably there is 
no universal treatment for women suffering from RPL and 
combination of therapies tailored for individual patient 
should be used.
Evidence coming from already conducted trials shows 
promising results for therapy of immune recurrent preg-
nancy loss. Most successful therapies seem to be IVIG, 
paternal lymphocyte therapy and combination corticos-
teroids + low dose acetylsalicylic acid + unfractioned 
heparin, GM-CSF, low dose aspirin + low molecular weight 
heparin. 
Although recurrent pregnancy loss research is difficult 
and full of controversies important progress has been made 
with hope for finally providing effective care for RPL suffer-
ing couples. 
113
Jan Modzelewski et al., Limphocytes in RPL
www. journals.viamedica.pl/ginekologia_polska
16. Robertson SA, Prins JR, Sharkey DJ, et al. Seminal fluid and the gen-
eration of regulatory T cells for embryo implantation. Am J Reprod 
Immunol. 2013; 69(4): 315–330, doi: 10.1111/aji.12107, indexed in 
Pubmed: 23480148.
17. Robertson SA, Ingman WV, O’Leary S, et al. Transforming growth factor 
beta--a mediator of immune deviation in seminal plasma. J Reprod Im-
munol. 2002; 57(1-2): 109–128, indexed in Pubmed: 12385837.
18. Jasper MJ, Tremellen KP, Robertson SA. Reduced expression of IL-6 and 
IL-1alpha mRNAs in secretory phase endometrium of women with recur-
rent miscarriage. J Reprod Immunol. 2007; 73(1): 74–84, doi: 10.1016/j.
jri.2006.06.003, indexed in Pubmed: 17034864.
19. Zhu L, Chen H, Liu M, et al. Treg/Th17 Cell Imbalance and IL-6 Profile in 
Patients With Unexplained Recurrent Spontaneous Abortion. Reprod 
Sci. 2017; 24(6): 882–890, doi: 10.1177/1933719116670517, indexed in 
Pubmed: 27698192.
20. Saifi B, Rezaee SA, Tajik N, et al. Th17 cells and related cytokines in 
unexplained recurrent spontaneous miscarriage at the implantation 
window. Reprod Biomed Online. 2014; 29(4): 481–489, doi: 10.1016/j.
rbmo.2014.06.008, indexed in Pubmed: 25154016.
21. James JL, Saghian R, Perwick R, et al. Trophoblast plugs: impact on 
utero-placental haemodynamics and spiral artery remodelling. Hum 
Reprod. 2018 [Epub ahead of print], doi: 10.1093/humrep/dey225, 
indexed in Pubmed: 29955830.
22. Liu YS, Wu Li, Tong XH, et al. Study on the relationship between Th17 
cells and unexplained recurrent spontaneous abortion. Am J Reprod 
Immunol. 2011; 65(5): 503–511, doi: 10.1111/j.1600-0897.2010.00921.x, 
indexed in Pubmed: 21029245.
23. Lee SK, Kim JY, Hur SE, et al. An imbalance in interleukin-17-producing T 
and Foxp3 regulatory T cells in women with idiopathic recurrent preg-
nancy loss. Hum Reprod. 2011; 26(11): 2964–2971, doi: 10.1093/hum-
rep/der301, indexed in Pubmed: 21926059.
24. Ahmadi M, Ghaebi M, Abdolmohammadi-Vahid S, et al. NK cell frequency 
and cytotoxicity in correlation to pregnancy outcome and response to IVIG 
therapy among women with recurrent pregnancy loss. J Cell Physiol. 2018 
[Epub ahead of print], doi: 10.1002/jcp.27627, indexed in Pubmed: 30317625.
25. Egerup P, Lindschou J, Gluud C, et al. ImmuReM IPD Study Group. The 
effects of immunotherapy with intravenous immunoglobulins versus 
no intervention, placebo, or usual care in patients with recurrent 
miscarriages: a protocol for a systematic review with meta-analyses, 
trial sequential analyses, and individual patient data meta-analyses of 
randomised clinical trials. Syst Rev. 2014; 3(10): 89, doi: 10.1186/2046-
4053-3-89, indexed in Pubmed: 25128005.
26. Wong LF, Porter TF, Scott JR. Immunotherapy for recurrent mis-
carriage. Cochrane Database Syst Rev. 2014(10): CD000112, doi: 
10.1002/14651858.CD000112.pub3, indexed in Pubmed: 25331518.
27. Cavalcante MB, Sarno M, Araujo Júnior E, et al. Lymphocyte immuno-
therapy in the treatment of recurrent miscarriage: systematic review 
and meta-analysis. Arch Gynecol Obstet. 2017; 295(2): 511–518, doi: 
10.1007/s00404-016-4270-z, indexed in Pubmed: 28004193.
28. Liu M, Zhen X, Song H, et al. Low-dose lymphocyte immunotherapy 
rebalances the peripheral blood Th1/Th2/Treg paradigm in patients with 
unexplained recurrent miscarriage. Reprod Biol Endocrinol. 2017; 15(1): 
95, doi: 10.1186/s12958-017-0315-9, indexed in Pubmed: 29246150.
29. Motak-Pochrzest H, Malinowski A. Polish experiences with paternal 
lymphocyte immunization in women with recurrent miscarriages. Neuro 
Endocrinol Lett. 2015; 36(6): 572–577, indexed in Pubmed: 26812293.
30. Cetin O, Karaman E, Cim N, et al. The impact of low molecular weight hep-
arin on obstetric outcomes among unexplained recurrent miscarriages 
complicated with methylenetetrahydrofolate reductase gene polymor-
phism. Ginekol Pol. 2017; 88(5): 260–265, doi: 10.5603/GP.a2017.0049, 
indexed in Pubmed: 28580572.
31. Lv S, Yu J, Xu X. A comparison of effectiveness among frequent 
treatments of recurrent spontaneous abortion: A Bayesian network 
meta-analysis. Am J Reprod Immunol. 2018; 80(1): e12856, doi: 
10.1111/aji.12856, indexed in Pubmed: 29709100.
Acknowledgements
Possible conflict of interest — JM and AK are ESHRE 
members.
JM participated in all stages of project. AK and MR de-
signed project, participated in data analysis and reviewed 
final manuscript. AK proofread the manuscript. MR super-
vised the project.
This project had no external financial support.
REFERENCES
1. Medawar P. Some immunological and endocrinological problems 
raised by the evolution of viviparity in vertebrates. Symp Soc Exp Biol. 
1953; 7: 320–337.
2. Szekeres-Bartho J. The Role of Progesterone in Feto-Maternal Im-
munological Cross Talk. Med Princ Pract. 2018; 27(4): 301–307, doi: 
10.1159/000491576, indexed in Pubmed: 29949797.
3. Sharma S, Godbole G, Modi D. Decidual Control of Trophoblast Invasion. 
Am J Reprod Immunol. 2016; 75(3): 341–350, doi: 10.1111/aji.12466, 
indexed in Pubmed: 26755153.
4. Faas MM, de Vos P. Uterine NK cells and macrophages in pregnancy. 
Placenta. 2017; 56: 44–52, doi: 10.1016/j.placenta.2017.03.001, indexed 
in Pubmed: 28284455.
5. Qian J, Zhang Na, Lin J, et al. Distinct pattern of Th17/Treg cells in preg-
nant women with a history of unexplained recurrent spontaneous abor-
tion. Biosci Trends. 2018; 12(2): 157–167, doi: 10.5582/bst.2018.01012, 
indexed in Pubmed: 29657243.
6. Atik RB, Christiansen O, Elson J, et al. ESHRE guideline: recurrent 
pregnancy loss. Human Reproduction Open. 2018; 2018(2), doi: 
10.1093/hropen/hoy004.
7. El Hachem H, Crepaux V, May-Panloup P, et al. Recurrent pregnancy 
loss: current perspectives. Int J Womens Health. 2017; 9: 331–345, doi: 
10.2147/IJWH.S100817, indexed in Pubmed: 28553146.
8. Łuczak-Wawrzyniak J, Czarnecka-Iwańczuk M, Bukowska A, et al. Early 
and late psychological effects of pregnancy loss. Ginekol Pol. 2010; 
81(5): 374–377, indexed in Pubmed: 20568519.
9. Christiansen O, Steffensen R, Nielsen H, et al. Multifactorial Etiol-
ogy of Recurrent Miscarriage and Its Scientific and Clinical Implica-
tions. Gynecologic and Obstetric Investigation. 2008; 66(4): 257–267, 
doi: 10.1159/000149575.
10. Sandquist I, Kolls J. Update on regulation and effector functions of Th17 
cells. F1000Res. 2018; 7: 205, doi: 10.12688/f1000research.13020.1, 
indexed in Pubmed: 29527301.
11. Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for 
the generation of pathogenic effector TH17 and regulatory T cells. Na-
ture. 2006; 441(7090): 235–238, doi: 10.1038/nature04753, indexed in 
Pubmed: 16648838.
12. Gagliani N, Amezcua Vesely MC, Iseppon A, et al. Th17 cells transdif-
ferentiate into regulatory T cells during resolution of inflammation. 
Nature. 2015; 523(7559): 221–225, doi: 10.1038/nature14452, indexed 
in Pubmed: 25924064.
13. Kawai K, Uchiyama M, Hester J, et al. Regulatory T cells for tolerance. Hum 
Immunol. 2018; 79(5): 294–303, doi: 10.1016/j.humimm.2017.12.013, 
indexed in Pubmed: 29288698.
14. Mori M, Bogdan A, Balassa T, et al. The decidua-the maternal bed em-
bracing the embryo-maintains the pregnancy. Semin Immunopathol. 
2016; 38(6): 635–649, doi: 10.1007/s00281-016-0574-0, indexed in 
Pubmed: 27287066.
15. Gong H, Chen Y, Xu J, et al. The regulation of ovary and conceptus on 
the uterine natural killer cells during early pregnancy. Reprod Biol 
Endocrinol. 2017; 15(1): 73, doi: 10.1186/s12958-017-0290-1, indexed 
in Pubmed: 28874155.
